![Logo](/assets/logo-d3f1fdf60522f0983e71f9fcc720cb7da5b55c0b748ed5bded3d2fbf81387bf0.png)
CORD-19:2008f024274c53b0de1276f4047a6a641813fd98 / 137738-138003
Annnotations
CORD-19-Sentences
{"project":"CORD-19-Sentences","denotations":[{"id":"T48311","span":{"begin":0,"end":265},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Therefore, an analysis of previously conducted asthma studies was undertaken to evaluate pediatric subjects aged 4-11 years (n=276) and adult subjects (n=85) previously receiving short-acting beta 2 -agoinsts alone in seven double-blind, randomized, 12-week trials."}
CORD-19_Custom_license_subset
{"project":"CORD-19_Custom_license_subset","denotations":[{"id":"T353","span":{"begin":0,"end":265},"obj":"Sentence"}],"text":"Therefore, an analysis of previously conducted asthma studies was undertaken to evaluate pediatric subjects aged 4-11 years (n=276) and adult subjects (n=85) previously receiving short-acting beta 2 -agoinsts alone in seven double-blind, randomized, 12-week trials."}
CORD-19-PD-MONDO
{"project":"CORD-19-PD-MONDO","denotations":[{"id":"T1142","span":{"begin":47,"end":53},"obj":"Disease"},{"id":"T1143","span":{"begin":62,"end":65},"obj":"Disease"}],"attributes":[{"id":"A1142","pred":"mondo_id","subj":"T1142","obj":"http://purl.obolibrary.org/obo/MONDO_0004979"},{"id":"A1143","pred":"mondo_id","subj":"T1143","obj":"http://purl.obolibrary.org/obo/MONDO_0010518"}],"text":"Therefore, an analysis of previously conducted asthma studies was undertaken to evaluate pediatric subjects aged 4-11 years (n=276) and adult subjects (n=85) previously receiving short-acting beta 2 -agoinsts alone in seven double-blind, randomized, 12-week trials."}
CORD-19-PD-HP
{"project":"CORD-19-PD-HP","denotations":[{"id":"T533","span":{"begin":47,"end":53},"obj":"Phenotype"}],"attributes":[{"id":"A533","pred":"hp_id","subj":"T533","obj":"http://purl.obolibrary.org/obo/HP_0002099"}],"text":"Therefore, an analysis of previously conducted asthma studies was undertaken to evaluate pediatric subjects aged 4-11 years (n=276) and adult subjects (n=85) previously receiving short-acting beta 2 -agoinsts alone in seven double-blind, randomized, 12-week trials."}